Welcome to the cusp of a new frontier. Biotechnology, an industry already catalyzed by AI and machine learning, is about to make another quantum leap. Scala Biodesign to redefine protein engineering landscape, fresh from a $5.5 million funding round. Born out of the Weizmann Institute of Science, Scala leverages the predictive powers of AlphaFold and RoseTTAfold to fundamentally alter the approach to designing therapeutic molecules. Let's dig in.
The Future Takes Shape:
Accelerated Engineering: Scala's method circumvents the laborious and costly trial-and-error process, substituting it with focused computational analysis. By predicting 3D protein structures, they fast-track the slowest part of therapeutic development, saving time and money.
Comments